Life Sciences at Goldman Sachs Alternatives
Overview
Life Sciences at Goldman Sachs Alternatives is a private equity investor that focuses on growth-oriented investments in early- to mid-stage therapeutic, life sciences tools, and diagnostics companies. The strategy targets areas of innovation such as precision medicine, genetic medicine, cell therapy, and immunotherapy.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| MapLight Therapeutics | Jul 2025 | Series D | Lead |
| Beacon Therapeutics | Jan 2026 | Series C | Lead |
| AirNexis Therapeutics | Jan 2026 | Series A | Co-investor |
| Sidewinder Therapeutics | Apr 2026 | Series B | Co-investor |
| Vaderis Therapeutics | Aug 2026 | Series B | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Life Sciences at Goldman Sachs Alternatives based?
Life Sciences at Goldman Sachs Alternatives is headquartered in New York City, New York, United States.
When was Life Sciences at Goldman Sachs Alternatives founded?
Life Sciences at Goldman Sachs Alternatives was founded in 2021.
How many portfolio companies does Life Sciences at Goldman Sachs Alternatives have?
Life Sciences at Goldman Sachs Alternatives has 5 portfolio companies in Caplight's dataset.
What are some companies in Life Sciences at Goldman Sachs Alternatives's portfolio?
Portfolio companies visible on Caplight include MapLight Therapeutics, Beacon Therapeutics, AirNexis Therapeutics, Sidewinder Therapeutics, Vaderis Therapeutics.
What was Life Sciences at Goldman Sachs Alternatives's most recent investment shown here?
Life Sciences at Goldman Sachs Alternatives's most recent investment in this portfolio sample was in Vaderis Therapeutics in 2026.
What sectors does Life Sciences at Goldman Sachs Alternatives focus on?
Life Sciences at Goldman Sachs Alternatives focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Life Sciences at Goldman Sachs Alternatives focus on?
Life Sciences at Goldman Sachs Alternatives typically invests at the Mid stage.
What is Life Sciences at Goldman Sachs Alternatives's AUM?
Life Sciences at Goldman Sachs Alternatives's assets under management are estimated between $650.0M and $650.0M.